Clinical Trial Search

Primary: Overall Response Rate — 24 Participants

Primary: Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) — 0; 1; 0; 4 Participants

Primary: Endorsed and Anticipated Stigma Inventory (EASI) — 57.9; 62.3; 57.5; 54.1 units on a scale

Primary: Assessment of the EnSite Precision™ Software V2.0 in Terms of Geometry Accuracy — 461; 34; 8 Participants

Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number

Primary: The Percentage Change in PASI (Psoriasis Area Severity Index) — -24.8; -40.2; -46.8; -29.8 percentage change in PASI — p==0.003

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.0; 98.0 percentage of participants

Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 21.3; 27.8; 26.4; 23.1 Percentage of participants

Primary: Mean of Per Subject Percentages of Target Lesions Judged to be Clear (PWA=0) at Visit 8 — 3.72; 49.5; 57.88 Per-Subject Percent of Lesions Clear

Primary: Part 1. Mean Change From Baseline in Rate-Corrected (Fridericia's) QT Interval (QTcF) at 0.5 Hours — 419.23; 418.08; 1.42; 1.90 milliseconds (msec)

Primary: Androxal Cmax Formulation A — 0.999; 1.67 ng/mL

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: Difference in Psoriasis Activity and Severity Index (PASI) Scores Between Week 12 of the First Treatment in Study C87040 [NCT00245765] and Week 12 of Re-treatment in…

Primary: Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS) — -40.6; -35.1; -33.6; -38.9 weekly hot flushes — p=<0.001

Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 57.2; 59.3 mL — p=<0.001